165 related articles for article (PubMed ID: 24088734)
1. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.
Mehra R; Zhu F; Yang DH; Cai KQ; Weaver J; Singh MK; Nikonova AS; Golemis EA; Flieder DB; Cooper HS; Lango M; Ridge JA; Burtness B
Clin Cancer Res; 2013 Dec; 19(23):6633-43. PubMed ID: 24088734
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
3. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
Hao D; Lau HY; Eliasziw M; Box A; Diaz R; Klimowicz AC; Shin B; Lees-Miller SP; Magliocco AM
Head Neck; 2012 Jun; 34(6):785-91. PubMed ID: 22127805
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.
Patel MR; Zhao N; Ang MK; Stadler ME; Fritchie K; Weissler MC; Zanation AM; Harris SL; Funkhouser WK; Olshan AF; Shores CG; Hayes DN
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):587-95. PubMed ID: 23846458
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.
Jun HJ; Ahn MJ; Kim HS; Yi SY; Han J; Lee SK; Ahn YC; Jeong HS; Son YI; Baek JH; Park K
Br J Cancer; 2008 Jul; 99(1):167-72. PubMed ID: 18594541
[TBL] [Abstract][Full Text] [Related]
6. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer.
An HJ; Jo H; Jung CK; Kang JH; Kim MS; Sun DI; Cho KJ; Cho JH; Won HS; Sun S; Ko YH
Pathol Res Pract; 2017 Aug; 213(8):949-955. PubMed ID: 28645807
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy.
Bišof V; Jakovčević A; Seiwerth S; Rakušić Z; Gašparov S
J Cancer Res Clin Oncol; 2013 Feb; 139(2):187-94. PubMed ID: 23011763
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
11. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
Gao Y; Liu D
Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
[TBL] [Abstract][Full Text] [Related]
12. DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors.
Lima LM; de Souza LR; da Silva TF; Pereira CS; Guimarães AL; de Paula AM; de Andrade Carvalho H
Histopathology; 2012 Feb; 60(3):489-96. PubMed ID: 22176134
[TBL] [Abstract][Full Text] [Related]
13. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
15. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.
Ang MK; Patel MR; Yin XY; Sundaram S; Fritchie K; Zhao N; Liu Y; Freemerman AJ; Wilkerson MD; Walter V; Weissler MC; Shockley WW; Couch ME; Zanation AM; Hackman T; Chera BS; Harris SL; Miller CR; Thorne LB; Hayward MC; Funkhouser WK; Olshan AF; Shores CG; Makowski L; Hayes DN
Clin Cancer Res; 2011 Oct; 17(20):6542-52. PubMed ID: 21908577
[TBL] [Abstract][Full Text] [Related]
16. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.
Chen WH; Xin PL; Pan QX; Chen YY; Wang CR; Zhang ZS; Chen YF; Zhang CY; Cai WJ
PLoS One; 2014; 9(9):e106600. PubMed ID: 25191856
[TBL] [Abstract][Full Text] [Related]
18. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
Hayes M; Lan C; Yan J; Xie Y; Gray T; Amirkhan RH; Dowell JE
Anticancer Res; 2011 Dec; 31(12):4135-9. PubMed ID: 22199271
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
